The farnesyltransferase inhibitor, FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells

International Journal of Oncology

Volumn 12, Issue 1, 1998, Pages 137-140

  Hung, Wen Chun ^a   Chaung, Lea Yea ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Bax; Bcl xs; Farnesyltransferase; FPT inhibitor III; Ovarian cancer

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; ENZYME INHIBITOR; FARNESYL DIPHOSPHATE; FARNESYL TRANS TRANSFERASE; ISOPRENOID PHOSPHATE; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; TRANSFERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; HUMAN; HUMAN CELL; ONCOGENE RAS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL CULTURE; CELL DIVISION; CHEMISTRY; CHROMATIN; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; METABOLISM; OVARY TUMOR; PATHOLOGY; UPREGULATION; WESTERN BLOTTING;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL DIVISION; CHROMATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; POLYISOPRENYL PHOSPHATES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031974135     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.1.137     Document Type: Article

References (28)

1. Wittinghofer A and Pai EF: The structure of Ras protein: a model for molecular switch. Trends Biochem Sci 16: 382-387, 1991.
2. Barbacid M: ras genes. Annu Rev Biochem 56: 779-827, 1987.
3. Lowy D and Willumsen B: Regulators and effectors of Ras. Annu Rev Biochem 62: 851-891, 1993.
4. Prendergast GC and Gibbs JB: Pathways of Ras function: connections to the actin cytoskeleton. Adv Cancer Res 62: 19-63, 1993.
5. Schlessinger J: How receptor tyrosine kinases activates Ras. Trends Biochem Sci 18: 273-275, 1993.
6. Cano E and Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20: 117-122, 1995.
7. Khosravifar R and Der CJ: The ras signal transduction pathway. Cancer Metastasis Rev 13: 67-89, 1994.
8. Bar-Sagi D and Feramisco JR: Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 42: 841-848, 1985.
9. Hagag N, Halegoua S and Viola M: Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21. Nature 319: 680-682, 1986.
10. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
11. Hancock J, Magee A, Childs J and Marshall C: All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177, 1989.
12. Casey PJ, Solski PA, Der CJ and Buss JE: p21 ras is modified by a farnesyl isopreoid. Proc Natl Acad Sci USA 86: 8323-8327, 1989.
13. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE and Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992.
14. Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, Brenner DA and Der CJ: The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylated or myristylated, oncogene ras signaling and transformation. J Biol Chem 269: 19203-19206, 1994.
15. Gibbs JB: Ras C-terminal processing enzymes: new drug targets. Cell 65: 1-4, 1991.
16. Hung WC, Chai CC, Huang JS and Chuang LY: Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Human Pathol 27: 1324-1328, 1996.
17. Manne V, Ricca CS, Brown JG, Tuomari AV, Van N, Patel D, Schmidt R, Lynch MJ, Ciosek CP, Carboni JM, Robinson S, Gordon EM, Barbacid M, Seizinger BR and Biller SA: Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyl-transferase. Drug Dev Res 34: 121-137, 1995.
18. Hung WC, Huang JH and Chuang LY: Antisense oligodeoxy-nuclotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression. Biochem Biophys Res Commun 220: 719-723, 1996.
19. Chuang LY, Hung WC, Chang CC and Tsai JH: Characterization of apoptosis induced by transforming growth factor ß 1 in human hepatoma cells. Anticancer Res 14: 147-152, 1994.
20. Hancock JF, Cadwallader K, Paterson H and Marshall CJ: A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of Ras proteins. EMBO J 10: 4033-4039, 1991.
21. Porfiri E, Evans T, Chardin P and Hancock JF: Prenylation of Ras proteins is required for efficient hSOS-promoted guanine nucleotide exchange. J Biol Chem 269: 22672-22677, 1994.
22. Carcia AM, Rowell C, Ackermann K, Kowalcyk JJ and Lewis MD: Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 268: 18415-18418, 1993.
23. Kohl NE, Wilson FR, Mosser SD, Giuliani E, De Solms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD, Gibbs JB and Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145, 1994.
24. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, Desolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Krai AM, Miller PJ, Mosser D, Oneill TJ, Rands E, Schaber MD, Gibbs JB and Oliff A: Inhibition of farnesyltransferase regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1: 792-797, 1995.
25. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ and McKenna WG: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56: 1727-1730, 1996.
26. Kinoshita T, Yokota T, Arai KI and Miyajima A: Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 10: 2207-2212, 1995.
27. Lebowitz PF, Casey PJ, Prendergast GC and Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of Rho B. J Biol Chem 272: 15591-15594, 1997.
28. Buss JH, Quilliam LA, Kato K, Casey PJ, Solski PA, Wong G, Clark R, McCornik F, Bokoch GM and Der CJ: The COOH-terminal domain of the RaplA protein is isoprenylated and supports transformation by an H-ras: RaplA chimeric protein. Mol Cell Biol 11: 1523-1530, 1991.